Covalon Technologies Ltd. to Exhibit at the Largest Annual Infection Prevention and Control Conference in the World
Covalon’s other ground-breaking infection-fighting products will also be on display, including SurgiClear™, a dual antimicrobial transparent post-operative dressing, and IV Clear™, an antimicrobial clear silicone adhesive securement dressing to cover and protect vascular access devices, both of which are proven to have a synergistic effect against some of the most commonly associated hospital-acquired infection bacteria.2
“APIC 2018 is a great opportunity for
APIC 2018 features the largest exhibition of leading-edge science and
technology dedicated to infection prevention and showcases innovative
products and services from more than 270 companies. It is the largest
annual gathering of infection prevention specialists from across
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
2 A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American Journal of Infection Control , Volume 43 , Issue 6 , S22